Monoclonal antibodies in the treatment of multiple myeloma: Current status and future perspectives

Leukemia

Volumn 30, Issue 3, 2016, Pages 526-535

  Lonial, S ^a   Durie, B ^b   Palumbo, A ^c   San Miguel, J ^d  

^a EMORY UNIVERSITY   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c UNIVERSITY OF TURIN   (Italy)

^d UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL ACTIVATING FACTOR; CD38 ANTIGEN; CD74 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; DACETUZUMAB; DARATUMUMAB; ELOTUZUMAB; INDATUXIMAB RAVTANSINE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; IPILIMUMAB; ISATUXIMAB; LIRILUMAB; LORVOTUZUMAB MERTANSINE; LUCATUMUMAB; MILATUZUMAB; MONOCLONAL ANTIBODY; MOR 202; NIVOLUMAB; OKT 8; PEMBROLIZUMAB; PIDILIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; SILTUXIMAB; SYNDECAN 1; TABALUMAB; ULOCUPLUMAB; UNCLASSIFIED DRUG; CXCR4 PROTEIN, HUMAN; IL6 PROTEIN, HUMAN; IMMUNOGLOBULIN RECEPTOR; IMMUNOLOGIC FACTOR; LEUKOCYTE ANTIGEN; PROTEASOME INHIBITOR; SIGNALING LYMPHOCYTIC ACTIVATION MOLECULE; SLAMF7 PROTEIN, HUMAN; TNFSF13B PROTEIN, HUMAN;

EFFECTOR CELL; ELECTROPHORESIS; HUMAN; IMMUNOFIXATION ELECTROPHORESIS; IMMUNOPHENOTYPING; MONOTHERAPY; MULTIPLE MYELOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; ANTAGONISTS AND INHIBITORS; APOPTOSIS; DISEASE FREE SURVIVAL; DRUG EFFECTS; GENE EXPRESSION; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; MORTALITY; PATHOLOGY; PLASMA CELL; TRENDS;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD; APOPTOSIS; B-CELL ACTIVATING FACTOR; DISEASE-FREE SURVIVAL; GENE EXPRESSION; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; INTERLEUKIN-6; MULTIPLE MYELOMA; PLASMA CELLS; PROTEASOME INHIBITORS; RECEPTORS, CXCR4; RECEPTORS, IMMUNOLOGIC; SIGNALING LYMPHOCYTIC ACTIVATION MOLECULE FAMILY;

EID: 84959335825     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.223     Document Type: Review

References (112)

1. Kuehl WM, Bergsagel PL. Molecular pathogenesis of multiple myeloma and its premalignant precursor. J Clin Invest 2012; 122: 3456-3463
2. National Cancer Institute SEER database. Surveillance, Epidemiology, and End Results Program. 2014 [cited June 30]. Available from http://seer.cancer.gov/
3. Becker N. Epidemiology of multiple myeloma. In: Moehler T, Goldschmidt H (eds). Multiple Myeloma: Recent Results in Cancer Research. Springer-Verlag: Berlin Heidelberg, Germany, 2011 25-35
4. Walker BA, Wardell CP, Melchor L, Brioli A, Johnson DC, Kaiser MF, et al. Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. Leukemia 2014; 28: 384-390
5. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009; 23: 3-9
6. Cömert M, Günes AE, Sahin F, Saydam G. Quality of life and supportive care in multiple myeloma. Turk J Haematol 2013; 30: 234-246
7. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 2516-2520
8. Rovira M, Rosiñol L, Fernández-Avilés F, Martinez C, Giné E, Esteve J, et al. Is there a curative potential of autologous stem cell transplantation in multiple myeloma?. Long-Term results from a single-centre series. Bone Marrow Transplant 2009; 42: S147 (abstract P592
9. Gahrton G, Svensson H, Cavo M, Apperly J, Bacigalupo A, Björkstrand B, et al. Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-8 at European Group for Blood and Marrow Transplantation centres. Br J Haematol 2001; 113: 209-216
10. Wildes TM, Rosko A, Tuchman SA. Multiple myeloma in the older adult: better prospects, more challenges. J Clin Oncol 2014; 32: 2531-2540
11. Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia 2012; 26: 149-157
12. Zangari M, Tricot G, Polavaram L, Zhan F, Finlayson A, Knight R, et al. Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone. J Clin Oncol 2010; 28: 132-135
13. Mateos MV, San Miguel JF. Safety and efficacy of subcutaneous formulation of bortezomib versus the conventional intravenous formulation in multiple myeloma. Ther Adv Hematol 2012; 3: 117-124
14. Glasmacher A, Hahn C, Hoffmann F, Naumann R, Goldschmidt H, von Lilienfeld-Toal M, et al A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br J Haematol 2006; 132: 584-593
15. Dimopoulos MA, Richardson PG, Moreau P, Anderson KC. Current treatment landscape for relapsed and/or refractory multiple myeloma. Nat Rev Clin Oncol 2015; 12: 42-54
16. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer 2012; 12: 278-287
17. Malavasi F, Deaglio S, Funaro A, Ferrero E, Horenstein AL, Ortolan E, et al. Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology. Physiol Rev 2008; 88: 841-886
18. Chillemi A, Zaccarello G, Quarona V, Ferracin M, Ghimenti C, Massaia M, et al. Anti-CD38 antibody therapy: windows of opportunity yielded by the functional characteristics of the target molecule. Mol Med 2013; 19: 99-108
19. Quarona V, Ferri V, Chillemi A, Bolzoni M, Mancini C, Zaccarello G, et al. Unraveling the contribution of ectoenzymes to myeloma life and survival in the bone marrow niche. Ann N Y Acad Sci 2015; 1335: 10-22
20. Vaisitti T, Audrito V, Serra S, Buonincontri R, Sociali G, Mannino E, et al. The enzymatic activities of CD38 enhance CLL growth and trafficking: implications for therapeutic targeting. Leukemia 2015; 29: 356-368
21. Lin P, Owens R, Tricot G, Wilson CS. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol 2004; 121: 482-488
22. de Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DC, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol 2011; 186: 1840-1848
23. Overdijk MB, Verploegen S, Marjin B, van Egmond M, Groen WJ, Martens ACM, et al. Phagocytosis in a mechanism of action for daratumumab. 54th American Society of Hematology (ASH) Annual Meeting, Atlanta, GA, USA, 8-11 December 2012 (abstract 4054
24. Groen RW, van der Veer M, Hofhuis FM, van Kessel V, de Weers M, Parren PWHI, et al. In vitro and in vivo efficacy of CD38 directed therapy with daratumumab in the treatment of multiple myeloma. 52nd American Society of Hematology (ASH) Annual Meeting, Orlando, FL, USA, 4-7 December 2010 (abstract 3058
25. Jensen JHM, Boross P, Overdijk MB, Lammerts van Bueren JJ, Parren PWHI, Leusen JHW. Daratumumab, a human CD38 antibody induces apoptosis of myeloma tumor cells via Fc receptor-medicated crosslinking. 54th American Society of Hematology (ASH) Annual Meeting, Atlanta, GA, USA, 8-11 December 2012 (abstract 2974
26. Mutis T, de Weers M, van der Veer MS, Kessel BV, Bakker JM, Wittebol S, et al. The potential of the human CD38-specific antibody daratumumab to improve the antimyeloma effect of novel multidrug therapies including patients refractory to lenalidomide or bortezomib. American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, USA, 3-7 June 2011 (abstract e18571
27. van der Veer MS, de Weers M, van Kessel B, Bakker JM, Wittebol S, Parren PW, et al. The therapeutic human CD38 antibody daratumumab improves the antimyeloma effect of newly emerging multi-drug therapies. Blood Cancer J 2011; 1: e41
28. Laubach JP, Richardson PG. CD38-Targeted immunochemotherapy in refractory multiple myeloma: a new horizon. Clin Cancer Res 2015; 21: 2660-2662
29. Lokhorst H, Laubach J, Nahi H, Plesner T, Gimsing P, Hansson M, et al. Dosedependent efficacy of daratumumab (DARA) as monotherapy in patients with relapsed or refractory multiple myeloma (RRMM). American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, USA, 30 May-3 June 2014 (presentation no. 8513
30. Laubach JP, Tai YT, Richardson PG, Anderson KC. Daratumumab granted breakthrough drug status. Expert Opin Investig Drugs 2014; 23: 445-452
31. Lonial S, Weiss B, Usmani S, Singhal S, Chari A, Bahlis N, et al. Phase 2 study of daratumumab (DARA) in patients with 3 lines of prior therapy or double refractory multiple myeloma: 54767414MMY2002 (Sirius). American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, USA, 29 May-2 June 2015 (oral presentation LBA8512
32. Plesner T, Arkenau HT, Lokhorst HM, Gimsing P, Krejcik J, Lemech C, et al. Safety and efficacy of Daratumumab with Lenalidomide and Dexamethasone in relapsed or relapsed, refractory multiple myeloma. 56th American Society of Hematology (ASH) Annual Meeting and Exposition, San Francisco, CA, USA, 6-9 December 2014 (oral presentation 84
33. Mateos MV, Moreau P, Comenzo R, Bladé J, Benboubker L, de la Rubia J, et al. An ppen-label, multicenter, phase 1b study of daratumumab in combination with oomalidomide-dexamethasone and with backbone regimens in patients with multiple myeloma. 20th Congress of European Hematology Association (EHA), Vienna, Austria, 11-14 June 2015 (abstract P275
34. Lokhorst H, Plesner T, Gimsing P, Nahi H, Lisby S, Richardson P. DARATUMUMAB, a CD38 monoclonal antibody study in advanced multiple myeloma-An openlabel, dose escalation followed by open-label extension in a single-Arm Phase I/II study. 18th Congress of the European Hematology Association, Stockholm, Sweden, 13-16 June 2013 (presentation no. S576
35. Plesner T, Arkenau H-T, Lokhorst HM, Gimsing P, Krejcik J, Lemech CR, et al. Safety and efficacy of daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma. American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, USA, 30 May-3 June 2014 (poster
36. Deckert J, Wetzel MC, Bartle LM, Skaletskaya A, Goldmacher VS, Vallée F, et al. SAR650984, a novel humanized CD38-Targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies. Clin Cancer Res 2014; 20: 4574-4583
37. Genmab A/S. Webcast post-ASH Investor Seminar. Genmab A/S. 2013 [cited June 30]. Available from http://cache.merchantcantos.com/webcast/webcaster/4000/7464/16533/28919/Lobby/default.htm
38. Hann B, Cai T, Wang D, Hom Y-K, Aftab BT, Martin T, et al. SAR650984, an anti-CD38 antibody, shows anti-Tumor activity in a preclinical model of multiple myeloma. American Association for Cancer Research (AACR) Annual Meeting, Washington, DC, USA, 6-10 April 2013 (abstract 5469
39. Lejeune P, Blanc V, Courta J, Egile C, Vrignaud P, Deckert J, et al. In vivo therapeutic synergy of SAR650984, a humanized anti-CD38 antibody, in combination with melphalan in a multiple myeloma xenograft. 100th Annual Meeting AACR, Denver, CO, USA, 18-22 April 2009 (abstract 2797
40. Wetzel M-C, Nicolazzi C, Vallée F, Deckert J, Dumontet C, Plesa A, et al. SAR650984: characterization of a potent phase I humanized anti-CD38 antibody for the treatment of multiple myeloma and other hematologic malignancies. Cancer Res 2013; 73: (abstract 4735
41. Martin T, Strickland S, Glenn M, Hsu K, Charpentier E, Mikhael J A phase I trial of SAR650984, a CD38 monoclonal antibody, in relapsed or refractory multiple myeloma. American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, USA, 30 May-3 June 2014 (poster no. 8532
42. Martin TG, Baz R, Benson DM, Lendvai N, Campana F, Charpentier E, et al A Phase 1b dose escalation trial of SAR650984 (anti-CD-38 mAb) in combination with Lenalidomide and Dexamethasone in relapsed/refractory multiple myeloma. 56th American Society of Hematology (ASH) Annual Meeting and Exposition, San Francisco, CA, USA, 6-9 December 2014 (oral presentation 83
43. Martin T, Baz R, Benson D, Lendvai N, Hsu K, Charpentier E, et al A phase Ib dose escalation trial of SAR650984 (anti-CD-38 mAb) in combination with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma. American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, USA, 30 May-3 June 2014 (abstract 8512
44. Endell J, Samuelsson C, Boxhammer R, Strauβ S, Steidl S. Effect of MOR202, a human CD38 antibody, in combination with lenalidomide and bortezomib on bone lysis and tumor load in a physiological model of myeloma. American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, USA, 3-6 June 2011 (poster no. 8078
45. Boxhammer R, Wurzenberger C, Ness D, Steidl S, Endell J. The activity of MOR202, a fully human anti-CD38 antibody, is complemented by ADCP and is synergistically enhanced by lenalidomide in vitro and in vivo. 54th American Society of Hematology (ASH) Annual Meeting, Atlanta, GA, USA, 8-11 December 2012 (poster no. 4018
46. Boxhammer R, Steidl S, Endell J. Effect of IMiD compounds on CD38 expression on multiple myeloma cells: MOR202, a human CD38 antibody in combination with pomalidomide. American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, USA, 29 May-2 June 2015 (abstract 8588
47. Endell J. From library to bedside: potential of the anti-CD38 antibody MOR202 in combination therapy of multiple myeloma. Bio M. 2013; [cited June 30]. Available from http://www.m4.de/uploads/media/m4-Seminar-12112013-Endell-web.pdf
48. Raab MS, Goldschmidt H, Agis H, Blau I, Einsele H, Englehardt MM, et al A phase I/IIa study of the human anti-CD38 antibody MOR202 (MOR03087) in relapsed or refractory multiple myeloma (rrMM). American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, USA, 29 May-2 June 2015 (abstract 8574
49. Lammerts van Bueren J, Jakobs D, Kaldenhoven N, Roza M, Hiddingh S, Meesters J, et al. Direct in vitro comparison of Daratumumab with surrogate analogs of CD38 antibodies MOR03087, SAR650984 and Ab79. 56th American Society of Hematology (ASH) Annual Meeting and Exposition, San Francisco, CA, USA, 6-9 December 2014 (abstract 3474
50. Palumbo A, Rajkumar SV, San Miguel JF, Larocca A, Niesvizky R, Morgan G, et al. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol 2014; 32: 587-600
51. McCudden P, Axel A, Slaets D, Frans S, Bald J, Schecter JM, et al. Assessing clinical response in multiple myeloma (MM) patients treated with monoclonal antibodies (mAbs): validation of a daratumumab IFE reflex assay to distinguish malignant M-protein from therapeutic antibody. American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, USA, 29 May-2 June 2015 (abstract 8590
52. Hsi ED, Steinle R, Balasa B, Szmania S, Draksharapu A, Shum BP, et al. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res 2008; 14: 2775-2784
53. Veillette A, Guo H. CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma. Crit Rev Oncol Hematol 2013; 88: 168-177
54. Tai Y-T, Soydan E, Song W, Fulciniti M, Kim K, Hong F, et al. Retraction. CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells. Blood 2010; 115: 2983
55. Tai YT, Dillon M, Song W, Leiba M, Li XF, Burger P, et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood 2008; 112: 1329-1337
56. Collins SM, Bakan CE, Swartzel GD, Hofmeister CC, Efebera YA, Kwon H, et al. Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC. Cancer Immunol Immunother 2013; 62: 1841-1849
57. Zonder JA, Mohrbacher AF, Singhal S, van Rhee F, Bensinger WI, Ding H, et al A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood 2012; 120: 552-559
58. Jakubowiak AJ, Benson DM, Bensinger W, Siegel DS, Zimmerman TM, Mohrbacher A, et al. Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma. J Clin Oncol 2012; 30: 1960-1965
59. Jakubowiak AJ, Offidani M, Pegourie B, de la Rubia J, Garderet L, Laribi K, et al A randomized phase II study of bortezomib (Btz)/dexamethasone (dex) with or without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RRMM). American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, USA, 29 May-2 June 2015 (abstract 8573
60. Mateos MV, Granell M, Rocafiguera AO, Lopez JM, Bladé J, Hernandez MT, et al A phase II single-Arm safety study of elotuzumab in combination with thalidomide and low dose dexamethasone in patients with relapsed and/or refractory multiple myeloma. 19th Congress of European Haematology Association, Milan, Italy, 12-15 June 2014 (abstract P959
61. Lonial S, Vij R, Harousseau JL, Facon T, Moreau P, Mazumder A, et al. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J Clin Oncol 2012; 30: 1953-1959
62. Lonial S, Jagannath S, Moreau P, Jakubowiak AJ, Raab MS, Facon T, et al. Phase (Ph) I/II study of elotuzumab (Elo) plus lenalidomide/dexamethasone (Len/dex) in relapsed/refractory multiple myeloma (RR MM): updated Ph II results and Ph I/II long-Term safety. American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, USA, 31 May-4 June 2013 (presentation
63. Richardson PG, Jagannath S, Moreau P, Jakubowiak A, Raab MS, Facon T, et al A Phase 2 study of elotuzumab in combination with lenalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma: updated results. 54th American Society of Hematology (ASH) Annual Meeting, Atlanta, GA, USA, 8-11 December 2012 (presentation no. 202
64. Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, et al. ELOQUENT-2: a phase 3, randomized, ppen-label study of lenalidomide/dexamethasone with/without elotuzumab in patients with relapsed/refractory multiple myeloma. American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, USA, 29 May-2 June 2015 (oral presentation 8508
65. Usmani SZ, Sexton R, Ailawadhi S, Shah JJ, Callander NS, Zimmerman T, et al. SWOG 1211: initial report on Phase I trial of RVD-Elotuzumab for newly diagnosed high risk multiple myeloma (HRMM). 56th American Society of Hematology (ASH) Annual Meeting and Exposition, San Francisco, CA, USA, 6-9 December 2014 (abstract 4762
66. Benson Jr. DM, Bakan CE, Zhang S, Collins SM, Liang J, Srivastava S, et al. IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect. Blood 2011; 118: 6387-6391
67. Kohrt HE, Godwin JE, Lossos IS, Williams ME, Timmerman J, Link BK, et al A phase 1b, open-label, multicenter study of urelumab (BMS-663513) in combination with rituximab in subjects with relapsed/refractory B-cell malignancies. American Society of Clinical Oncology (ASCO) Annual Meeeting, Chicago, IL, USA, 31 May-4 June 2013 (abstract TPS3108
68. Kishimoto T. The biology of interleukin-6. Blood 1989; 74: 1-10
69. Chauhan D, Uchiyama H, Akbarali Y, Urashima M, Yamamoto K, Libermann TA, et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood 1996; 87: 1104-1112
70. Hilbert DM, Kopf M, Mock BA, Köhler G, Rudikoff S. Interleukin 6 is essential for in vivo development of B lineage neoplasms. J Exp Med 1995; 182: 243-248
71. Hata H, Xiao H, Petrucci MT, Woodliff J, Chang R, Epstein J. Interleukin-6 gene expression in multiple myeloma: a characteristic of immature tumor cells. Blood 1993; 81: 3357-3364
72. Voorhees PM, Chen Q, Small GW, Kuhn DJ, Hunsucker SA, Nemeth JA, et al. Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death. Br J Haematol 2009; 145: 481-490
73. Voorhees PM, Chen Q, Kuhn DJ, Small GW, Hunsucker SA, Strader JS, et al. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma. Clin Cancer Res 2007; 13: 6469-6478
74. Hunsucker SA, Magarotto V, Kuhn DJ, Kornblau SM, Wang M, Weber DM, et al. Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma. Br J Haematol 2011; 152: 579-592
75. Voorhees PM, Manges RF, Sonneveld P, Jagannath S, Somlo G, Krishnan A, et al A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma. Br J Haematol 2013; 161: 357-366
76. Orlowski RZ, Gercheva L, Williams C, Sutherland H, Robak T, Masszi T, et al A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma. Am J Hematol 2015; 90: 42-49
77. San-Miguel J, Bladé J, Shpilberg O, Grosicki S, Maloisel F, Min CK, et al. Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma. Blood 2014; 123: 4136-4142
78. Thomas SK, Suvorov A, Noens L, Rukavitsin O, Fay J, Wu KL, et al. Evaluation of the QTc prolongation potential of a monoclonal antibody, siltuximab, in patients with monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, or low-volume multiple myeloma. Cancer Chemother Pharmacol 2014; 73: 35-42
79. Neri P, Kumar S, Fulciniti MT, Vallet S, Chhetri S, Mukherjee S, et al. Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model. Clin Cancer Res 2007; 13: 5903-5909
80. Moreaux J, Legouffe E, Jourdan E, Quittet P, Rème T, Lugagne C, et al. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 2004; 103: 3148-3157
81. Raje NS, Hohl RJ, Faber EA, Richardson PGG, Forero-Torres A, Schiller GJ, et al. Phase I study of LY2127399, a human anti-BAFF antibody, and bortezomib in patients with previously treated multiple myeloma. American Society of Clinical Oncology (ASCO) Annual Meeeting, Chicago, IL, USA, 3-7 June 2011 (abstract 8012
82. Raje NS, Faber EA, Richardson PG, Schiller GJ, Hohl RJ, Cohen AD, et al. Phase 1 study of tabalumab, a human anti-BAFF antibody and bortezomib in patients with previously-Treated multiple myeloma. 54th American Society of Hematology (ASH) Annual Meeting, Atlanta, GA, USA, 8-11 December 2012 (oral presentation 447
83. Burton JD, Ely S, Reddy PK, Stein R, Gold DV, Cardillo TM, et al. CD74 is expressed by multiple myeloma and is a promising target for therapy. Clin Cancer Res 2004; 10: 6606-6611
84. Stein R, Mattes MJ, Cardillo TM, Hansen HJ, Chang CH, Burton J, et al. CD74: a new candidate target for the immunotherapy of B-cell neoplasms. Clin Cancer Res 2007; 13: 5556s-5563s
85. Stein R, Smith MR, Chen S, Zalath M, Goldenberg DM. Combining milatuzumab with bortezomib, doxorubicin, or dexamethasone improves responses in multiple myeloma cell lines. Clin Cancer Res 2009; 15: 2808-2817
86. Kaufman JL, Niesvizky R, Stadtmauer EA, Chanan-Khan A, Siegel D, Horne H, et al. Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma. Br J Haematol 2013; 163: 478-486
87. Calame KL. Plasma cells: finding new light at the end of B cell development. Nat Immunol 2001; 2: 1103-1108
88. Ikeda H, Hideshima T, Fulciniti M, Lutz RJ, Yasui H, Okawa Y, et al. The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clin Cancer Res 2009; 15: 4028-4037
89. Heffner LT, Jagannath S, Zimmerman TM, Lee KP, Rosenblatt J, Lonial S, et al. BT062, an antibody-drug conjugate directed against CD138, given weekly for 3 weeks in each 4 week cycle: safety and further evidence of clinical activity. 54th American Society of Hematology (ASH) Annual Meeting, Atlanta, GA, USA, 8-11 December 2012 (poster presentation 4042
90. Kelly KR, Chanan-Khan A, Heffner LT, Somio G, Siegel DS, Zimmerman T, et al. Indatuximab ravtansine (BT062) in combination with Lenalidomide and low-dose Dexamethasone in patients with relapsed and/or refractory multiple myeloma: clinical activity in patients already exposed to Lenalidomide and Bortezomib. 56th American Society of Hematology (ASH) Annual Meeting and Exposition, San Francisco, CA, USA, 6-9 December 2014 (poster presentation 4736
91. Gouard S, Pallardy A, Gaschet J, Faivre-Chauvet A, Bruchertseifer F, Morgenstern A, et al. Comparative analysis of multiple myeloma treatment by CD138 antigen targeting with bismuth-213 and Melphalan chemotherapy. Nucl Med Biol 2014; 41: e30-e35
92. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000; 192: 1027-1034
93. Carter L, Fouser LA, Jussif J, Fitz L, Deng B, Wood CR, et al. PD-1: PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2. Eur J Immunol 2002; 32: 634-643
94. Atanackovic D, Luetkens T, Kröger N. Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma. Leukemia 2014; 28: 993-1000
95. Kearl TJ, Jing W, Gershan JA, Johnson BD. Programmed death receptor-1/programmed death receptor ligand-1 blockade after transient lymphodepletion to treat myeloma. J Immunol 2013; 190: 5620-5628
96. Lesokhin AM, Ansell SM, Armand P, Scott EC, Halwani A, Gutierrez M, et al. Preliminary results of a Phase I study of nivolumab (BMS-936558) in patients with relapsed or refractory lymphoid malignancies. 56th American Society of Hematology (ASH) Annual Meeting and Exposition, San Francisco, CA, USA, 6-9 December 2014 (abstract 291
97. Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994; 1: 405-413
98. Hussein M, Berenson JR, Niesvizky R, Munshi N, Matous J, Sobecks R, et al A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma. Haematologica 2010; 95: 845-848
99. Bensinger W, Maziarz RT, Jagannath S, Spencer A, Durrant S, Becker PS, et al A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma. Br J Haematol 2012; 159: 58-66
100. Agura E, Niesvizky R, Matous J, Munshi N, Hussein M, Parameswaran RV, et al. Dacetuzumab (SGN-40), lenalidomide, and weekly dexamethasone in relapsed or refractory multiple myeloma: multiple responses observed in a Phase 1b study. 51st American Society of Hematology (ASH) Annual Meeting, Atlanta, GA, USA, 5-9 December 2009 (abstract 2870
101. Chanan-Khan A, Wolf JL, Garcia J, Gharibo M, Jagannath S, Manfredi D, et al. Efficacy analysis from Phase I study of lorvotuzumab mertansine (IMGN901), used as monotherapy, in patients with heavily pre-Treated CD56-positive multiple myeloma-A preliminary efficacy analysis. 52nd American Society of Hematology (ASH) Annual Meeting, Orlando, FL, USA, 4-7 December 2010 (abstract 1962
102. Berdeja JG, Hernandez-Ilizaliturri F, Chanan-Khan A, Patel M, Kelly KR, Running KL, et al. Phase I study of lorvotuzumab mertansine (LM, IMGN901) in combination with lenalidomide (Len) and dexamethasone (Dex) in patients with CD56-positive relapsed or relapsed/refractory multiple myeloma (MM). 54th American Society of Hematology (ASH) Annual Meeting, Atlanta, GA, USA, 8-11 December 2012 (oral presentation 728
103. Berdeja JG. Lorvotuzumab mertansine: antibody-drug-conjugate for CD56+multiple myeloma. Front Biosci (Landmark Ed) 2014; 19: 163-170
104. Ghobrial IM, Perez M, Baz R, Richardson PG, Anderson KC, Sabbatini P, et al. Phase 1b study of the novel anti-CXCR4 antibody ulocuplumab (BMS-936564) in combination with Lenalidomide plus low-dose Dexamethasone, or with Bortezomib plus Dexamethasone in subjects with relapsed or refractory multiple myeloma. 56th American Society of Hematology (ASH) Annual Meeting and Exposition, San Francisco, CA, USA, 6-9 December 2014 (abstract 3483
105. Niesvizky R, Martin III TG, Bensinger WI, Alsina M, Siegel DS, Kunkel LA, et al. Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Clin Cancer Res 2013; 19: 2248-2256
106. Jakubowiak AJ, Dytfeld D, Griffith KA, Lebovic D, Vesole DH, Jagannath S, et al A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood 2012; 120: 1801-1809
107. Donato F, Gay F, Bringhen S, Troia R, Palumbo A. Monoclonal antibodies currently in Phase II and III trials for multiple myeloma. Expert Opin Biol Ther 2014; 14: 1127-1144
108. Atanackovic D, Panse J, Hildebrandt Y, Jadczak A, Kobold S, Cao Y, et al. Surface molecule CD229 as a novel target for the diagnosis and treatment of multiple myeloma. Haematologica 2011; 96: 1512-1520
109. Mateo G, Montalbán MA, Vidriales MB, Lahuerta JJ, Mateos MV, Gutiérrez N, et al. Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy. J Clin Oncol 2008; 26: 2737-2744
110. Yang J, Yi Q. Therapeutic monoclonal antibodies for multiple myeloma: an update and future perspectives. Am J Blood Res 2011; 1: 22-33
111. Durie BG, Harousseau JL, Miguel JS, Bladé J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467-1473; erratum in Leukemia 2007; 21: 1134
112. Bladé J, Samson D, Reece D, Apperley J, Björkstrand B, Gahrton G, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102: 1115-1123